Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 219,920 shares, a growth of 57.1% from the December 31st total of 139,996 shares. Approximately 23.5% of the company’s shares are short sold. Based on an average daily volume of 667,868 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 667,868 shares, the short-interest ratio is presently 0.3 days. Approximately 23.5% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on APVO shares. Wall Street Zen cut Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Price Performance

NASDAQ:APVO opened at $7.27 on Friday. The firm’s 50-day moving average price is $14.88 and its 200-day moving average price is $26.69. The company has a market capitalization of $7.27 million, a PE ratio of 0.00 and a beta of 1.47. Aptevo Therapeutics has a 1-year low of $6.88 and a 1-year high of $1,616.47.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($40.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($37.62) by ($2.52). Equities analysts anticipate that Aptevo Therapeutics will post -15.84 EPS for the current fiscal year.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.